RANK ligand (RANKL) is a central activator of the NF-κB pathway and can activate the NF-κB response in cancer with bone metastasis [87]; targeting the RANKL/RANK/NF-κB pathway has recently been proposed as an effective strategy in patients with bone metastases [93,94]. Here, NFKB1 is linked to bone metastasis.